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1. Introduction 
During the last few decades accumulated epidemiological, clinical, and experimental 
evidence has revealed the important role of human papillomavirus (HPV) in the 
development of cervical carcinomas, an association almost unique in cancer epidemiology. 
Several important questions have been answered and a large number of scientific studies 
have paved the way for the introduction of new and effective vaccines, which will hopefully 
diminish the incidence of HPV-related carcinomas and precursor lesions in forthcoming 
years (Crum et al., 2003; zur Hausen, 1977, 2008). However, the exact recognition and proper 
treatment of clinically important lesions often poses problems both to pathologists and 
gynecologists.  
Morphology remains the gold standard for lesion diagnosis, despite the fact that it can be 
hampered by inter- and intra-observer variability. Additionally, the contribution of 
morphology in the field of human papillomavirus research cannot be overemphasized, since 
cytologic and/or histologic examination allow the recognition of viral cytopathic effects, 
and, with the aid of immunohistochemical and other in situ techniques, may reveal the exact 
cells, in which some main interactions take place. Thus, the correlation of cellular alterations 
with new sensitive methods of detection either for human papillomavirus nucleic acids or 
for HPV-related intracellular interactions might lead both to the identification of different 
groups of lesions according to their clinical significance, as well as to the correct application 
of current morphological criteria.  
The following chapter will focus on those immunohistochemical methods that can facilitate 
or confirm the detection of intraepithelial lesions of cervical squamous epithelium (SILs) in 
biopsy specimens, additionally presenting in brief some data concerning the mechanisms by 
which these specific cellular targets are related to important actions of HPV oncoproteins. 
Finally, a short comment concerning the application in diagnosis of methods other than 
immunohistochemistry has been added. 
1.1 HPV in carcinogenesis 
In the last three decades a large number of scientific studies have focused on the subject of 
cervical carcinogenesis.  These resulted in the accumulation of data linking several types of 
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human papillomavirus to the development of cervical cancer (Bosch et al., 2002; Bosch et al., 
2006; Crum et al., 1984; zur Hausen, 1977, 2009). The revealed strong association led to the 
suggestion that HPV is not only the main cause of cervical cancer, but also a necessary cause 
(Walboomers et al., 1999). Human papillomavirus is associated with more than 99% of all 
cervical cancer cases. In addition, a significant percentage of vulvar, vaginal, penile, anal 
and perianal carcinomas are HPV-positive (Fuste et al., 2010; Gross & Pfister, 2004; Insinga 
et al., 2008; Munoz et al., 2006), often containing HPV 16 DNA (zur Hausen, 2009), while a 
fraction of carcinomas in other sites of the human body has also been linked to high-risk 
(HR) HPV infections. Percentages of HPV positivity observed in carcinomas of the 
anogenital region are presented in Table 1.  
Human papillomavirus is estimated to comprise a causal agent in 5% of human cancers and 
is associated with more human cancers than any other virus (Bergonzini et al., 2010).  
Among them, cervical cancer represents a well-studied prototype of a human tumor related 
to a viral infection. 
Vaginal carcinomas 60-91% 
Vulvar carcinomas 50% 
Penile carcinomas 30-50% 
Anal and perianal carcinomas 60-94% 
Table 1. Percentage of HPV detection in carcinomas of the anogenital region other than 
cervical carcinoma (Munoz et al., 2006; zur Hausen, 2009). 
The most common viral types detected in cervical carcinomas include HPV 16, 18, 45, 31, 
33, 52, 58, and 35 (Clifford et al., 2003; Munoz et al., 2003). The fraction of squamous cell 
carcinomas or adenocarcinomas attributable to HPV16 and HPV18, which comprise the 
two most common types, is 70% and 86%, respectively. The paradox is that, although 
infection with oncogenic types of HPV is very common, malignancy is a rare outcome. 
This difference in incidence between infection and cancer development reveals the 
significance of complex interactions between viral, environmental and host-related factors 
(Frazer, 2009; Moscicki et al., 2006; Snijders et al., 2006; Whiteside et al., 2008; zur Hausen, 
2008). Viral persistence is an important determinant in this sequence of events, while 
immune status, viral integration into the host DNA, and infection with multiple HPV 
genotypes have significant roles. These multiple interactions are reflected in the long 
interval between infection and invasive carcinoma detection, often spanning a period of 
15 to 25 years (zur Hausen 2008). Other factors that may modify the risk for HPV DNA-
positive women include smoking, the use of oral contraceptives, and previous exposure to 
other sexually transmitted diseases (Bosch et al., 2006; Collins et al., 2010; Luie et al., 2011; 
Munoz et al., 2006). 
In recent years a large number of scientific studies have resulted in the introduction of 
effective vaccines, which are expected to diminish the incidence of HPV-related carcinomas 
of the uterine cervix and other organs (Bogaardts et al., 2011; Frazer, 2009; Stanley, 2010; The 
FUTURE I/II Study Group, 2010; zur Hausen, 2008). Moreover, they are expected to reduce 
the incidence of intraepithelial HPV-related lesions. A large number of the latter are caused 
by non-carcinogenic HPV types and do not constitute precancerous lesions, but still may be 
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the cause of significant anxiety and distress for the patients. Furthermore, in rare instances 
they can give rise to life-threatening conditions, like recurrent respiratory papillomatosis. 
Another main result of human papilloma virus research was the introduction in clinical 
practice of new diagnostic techniques (Cuzick et al., 2006; Gravitt et al., 2008; Poljak & 
Kocjan, 2010; Snijders et al., 2010). These allow for a more precise evaluation of the 
following: a) the presence of HPV in biologic specimens and the viral type present, b) the 
viral load, and c) the presence of an HPV-associated lesion demanding further therapeutic 
measures in cytological or biopsy material.  
Finally, an important aspect of human papilloma virus research is the fact that the complex 
interactions between HPV oncoproteins and their multiple cellular targets offer to 
investigators the opportunity to study important cellular pathways related to the 
carcinogenic process in general.  
1.2 Interactions between HPV oncoproteins and cellular pathways 
High-risk mucosal HPVs encode three transforming proteins: E5, E6 and E7. Their multiple 
biological activities have been extensively studied in the last few decades; however, several 
aspects remain to be elucidated (McLaughlin-Drubin M & Münger K, 2009a). 
HPV E5 is able to transform mouse fibroblasts and keratinocytes in culture (Straight et al., 
1993). It is believed to contribute to early stages of carcinogenesis and works in concert with 
E6 and E7 (Talbert-Slagle & DiMaio, 2009; Hu et al., 2009). The latter proteins are necessary 
for the induction and maintenance of the transformed phenotype. They inhibit the function 
of tumor suppressors p53 and pRb, respectively, whereas their expression enables cells to 
bypass normal cell cycle checkpoints. 
One of the main actions of HPV E7 proteins is the interaction with the retinoblastoma tumor 
suppressor protein, pRB, which controls S-phase entry through association with E2F 
transcription factor family members. They also interact with the related pocket proteins, 
p107 and p130. High-risk HPV E7 targets pRB for proteasomal degradation, while low-risk 
HPV E7 binds pRB with lower efficiency (approximately 10-fold lower) than HR- HPV E7 
(McLaughlin-Drubin M & Münger K, 2009a; Munger et al., 1991). E7 proteins cause aberrant 
activation of cdk2 (cyclin dependent kinase 2), which is associated with cyclins E and A, as 
well as cdk inhibitors, mainly p21CIP1 and p27KIP1. E7 expression results in dysregulated 
expression of cyclins E and A (McLaughlin-Drubin M & Münger K, 2009b; Zerfass et al., 
1995). It also results in retaining differentiating keratinocytes in a DNA synthesis competent 
state. 
High-risk HPV E6 proteins target p53 for proteasomal degradation through association with 
the cellular ubiquitin ligase E6AP (McLaughlin-Drubin M & Münger K, 2009b; Scheffner et 
al., 1990). Low-risk HPV E6 proteins can also associate with E6AP; however, high-risk HPV 
proteins target p53 for ubiquitination. 
Furthermore, HR-HPV E6 and E7 proteins cooperate to generate mitotic defects and 
aneuploidy through induction of supernumerary centrosomes and multipolar mitoses in 
epithelial cells (Duensing et al., 2000), while genomic instability results in the addition of 
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molecular alterations. The detection of abnormal mitoses is a useful morphologic indicator 
of high-risk HPV-associated lesions (Crum et al. 1984). 
Finally, integration of HPV genome into host chromosomes is an important event in cervical 
carcinogenesis (Hopman et al., 2006; Pett & Coleman, 2007), which occurs frequently during 
malignant progression and may result in dysregulation of E6/E7 expression due to 
disruption of E2, with associated loss of the inhibitory E2 action. 
2. Immunohistochemical stains in the diagnosis of Squamous Intraepithelial 
Lesions (SIL) 
Clinical management of preinvasive cervical disease consists of confirmation of SIL 
diagnosis by histopathological examination, followed by treatment or careful follow-up of 
certain lesions, according to the current guidelines. Histopathological diagnosis of CIN is 
based on well-defined criteria. However, in certain cases distinguishing both low- and high-
grade lesions from their mimics may pose problems (Crum & Rose, 2006; Kostopoulou et al., 
2001; Kurman et al., 1992), even to experienced gynecologic pathologists. The distinction of 
florid reactive changes, immature metaplastic patterns, and atrophic changes from HPV-
induced alterations may cause difficulties. Attempts have been made to redefine the 
traditional criteria for lesion diagnosis, while other efforts aimed at the adoption of new, 
more objective methods, which might support the former (Bollmann et al., 2005; Cho et al., 
2005; Guillaud et al., 2005; Prasad et al., 1994; Salvia et al., 2004; Scheurer et al., 2007). 
However, studies attempting to correlate HPV presence and replication to certain 
cytohistologic alterations are becoming less frequent and/or fruitful. 
In recent years molecular studies have revealed several markers that might be of utility in 
the diagnosis of squamous intraepithelial lesions, including cellular proteins targeted 
directly by viral oncoproteins, and markers related to the cell cycle, which is disturbed by 
multiple actions of the virus, as summarized in the above paragraphs. The 
immunohistochemical stains that are currently in use in several laboratories worldwide, as 
well as some new promising markers are presented in the following text. The terms low 
grade squamous intraepithelial lesion (LSIL) and high grade squamous intraepithelial lesion 
(HSIL) will be used interchangeably with CIN1 and CIN2/3, respectively. 
2.1 p16 
One extensively studied marker is p16 INK4A (hereafter referred to as p16), a cyclin-
dependent kinase inhibitor. p16 decelerates the cell cycle and functions as a tumor 
suppressor, while having a role in cellular senescence. p16 affects pRb-mediated regulation 
of the G1/S transition (Lukas et al., 1995; Ohtani et al., 2004; Quelle et al., 1995; Serrano, 
1997; Sano et al., 1998). 
The expression of p16 is altered in several human tumors by deletions, mutations, or 
methylation (Cohen & Geradts, 1997; Nakashima et al., 1999; O’Neill & McCluggage, 2006; 
Ruas & Peters 1998) and has also been altered in cervical carcinoma cases. However, 
increased expression is often observed in HPV-related intraepithelial lesions and this is 
mainly attributed to the presence of a feedback loop, which depends on the status of 
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retinoblastoma protein (pRb) and the potential of high-risk HPV E7 protein to inactivate 
the latter (Lukas et al., 1995; Giarre et al., 2001; McLaughlin-Drubin & Münger, 2009b). 
Correlation has been reported between HR-HPV oncogene expression and high scores of 
p16 positivity (Andersson et al., 2006), and enhancement of p16 RNA level has been 
observed in vitro after immortalization by high-risk HPV types (Nakao et al., 1997). 
Despite the presence of high levels of p16 in SILs, its suppressor function is not normally 
exerted. 
Several groups of investigators have examined immunohistochemically the expression of 
p16 in cervical squamous intraepithelial lesions (reviewed by Kostopoulou et al., 2011) and 
its possible correlation with HR-HPV types and/or lesion “progression”. Indeed, p16 is one 
of the best studied markers in gynaecologic pathology. However, percentages of 
immunohistochemical positivity vary among different studies, as presented in Table 2. In 
the latter, studies published in the last ten years and including more than 100 cases of 
squamous intraepithelial lesions in histopathologic specimens are summarized, and the 
reported percentages of p16 immunopositivity are presented, together with the criteria and 
the antibodies used by the authors. Importantly, different criteria have been used for p16 
immunoreactivity evaluation, with some authors focusing only on diffuse 
immunopositivity, some reporting any type of immunostaining, and others reporting 
nuclear and cytoplasmic staining separately. It should be also noted that some authors 
interpret focal positivity as a false-positive reaction. Positivity in the studies presented 
below varied from 5.6% to 100% for low-grade lesions and from 45.2% to 100% for high-
grade lesions (Table 2). The percentage of immunopositivity observed in non-neoplastic 
epithelia also varied between 0% and 32.7%. 
In a recent study (Kostopoulou et al., 2011) the two basic patterns of immunoreactivity, 
that is focal and diffuse, were further subdivided into groups as following: Focal 
positivity was subdivided into cases with occasional positive cells, dispersed or in small 
groups, observed mainly in the lower epithelial layers, and cases with occasional positive 
cells, dispersed or in small groups, commonly above the parabasal layer. Diffuse 
positivity (Figure 1) in the horizontal plane involved either all epithelial layers, or only 
the basal, parabasal and intermediate layers, without extending to the upper third of the 
epithelium. In HSIL, only diffuse positivity was encountered, observed in 24/25 cases 
(96%). In LSIL 41/55 cases (74.5%) showed some type of positivity, most commonly 
focal/sporadic (Figures 2 and 3). Interestingly, three out of eight LSILs showing diffuse 
immunoreactivity were characterized by markedly increased nuclear dimensions in the 
upper epithelial layers in comparison to other lesions characterized as low-grade. Another 
interesting finding of the above study was the different HPV type distribution observed 
between the two patterns of sporadic/focal positivity, involving lower vs 
intermediate/upper epithelial layers, and probably reflecting an earlier sporadic 
expression of E7 in certain lesions (Kostopoulou et al., 2011). The percentage of high-risk 
or probable high-risk HPV associated LSILs positive for p16 was 71.4% (25/35). This was 
not significantly different from immunopositivity observed in low-risk HPV associated 
lesions. Moreover, study of the pertinent literature revealed that a significant percentage 
of LSILs testing positive for HR-HPV by PCR or HC2 does not exhibit any p16 
immunopositivity. The percentage of p16 positivity reported for HR-HPV positive LSILs 
varied from 32.4% to 94.4% (Ishikawa et al. 2006; Kalof et al., 2005; Kostopoulou et al., 
2011). 
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Reference 
Number 
of SILs 
examined
LSIL 
positivity
HSIL 
positivity
Non-
neoplastic
epithelia
Evaluation of 
staining 
Antibody used 
in the study 
Agoff et al., 
2003 
269 56.6% 84.5% 11.5% 
N and C
≥5% cells 
E6H4 
(MTM) 
Branca et al., 
2004 
137 35% 81.2% 0% N and/or C
Polyclonal 
(Abcam) 
Negri et al., 
2004 
127 74.7% 100% ND 
N and C
≥5% cells in 
lower third
CINtec p16 
Histology Kit 
(DakoCytomation) 
Volgareva et, 
al. 2004 
113 37.2% 45.2% 3.2% N and/or C
E6H4 
(MTM) 
Wang et al., 
2004 
113 72% 94.7% 32.7% 
Any
reactivity
E6H4 
(MTM) 
Dray et al., 
2005 
104 74.1% 96.1% 7.0% N and/or C
JC8 
(Biocare Medical) 
Murphy et 
al., 2005 
117 100% 98.7% 0% N or C 
p16 
(Pharmingen) 
Ishikawa et 
al., 2006 
141 24.5% 87.5% 0% 
Moderate and 
strong
E6H4 
(MTM) 
Focchi et al., 
2007 
153 90.9% 100% 7.9% 
C and N
≥5% cells
Ab7 16PO7 
(Neomarkers) 
Hariri & 
Oster, 2007 
140 71.4% 100% 6% 
Continuous 
basal and 
parabasal
p16 Histology Kit 
(Dako) 
Van Niekerk 
et al., 2007 
184 57.1% 96.9% 22.9% 
N and C
≥5% cells in 
each layer
E6H4 
(DakoCytomation) 
Godoy et al. 
2008 
115 50% 96.2% 0% C and N 
CINtec p16 Kit 
(Dako) 
Dijkstra et al., 
2010 
406 5.6% 96.7% ND 
Diffuse, >1/3 
of epithelium
Ab-4, 16P04 
(Lab Vision) 
Tan et al., 
2010 
129 26.7% 79.7% 0% 
N and C
≥5% cells
p16 
(NeoMarkers) 
LSIL: low-grade squamous intraepithelial lesion; HSIL: high-grade squamous intraepithelial lesion; N: 
nuclear; C: cytoplasmic; ND: no data  
a Only studies including more than 100 cases of squamous intraepithelial lesions in histopathologic 
specimens and published in the last ten years are presented. 
Table 2. p16 immunopositivity in low- and high- grade squamous intraepithelial lesions 
reported in the literaturea 
The results of the above studies point towards the use of p16 immunostain in conjunction 
with histopathologic evaluation. Addition of a consecutive p16-stained slide to the HE-
stained slides has been shown to improve significantly interobserver agreement for both 
punch and cone biopsies (Bergeron et al., 2010; Dijkstra et al., 2010; Horn et al., 2008), and to 
help in the identification of occult lesions (Ordi et al., 2008). The differential diagnosis from 
non-neoplastic alterations can be facilitated, especially in conjunction with other 
immunostains, as presented below. Moreover, lesion grading can be faster, especially 
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concerning aggressive-appearing low-grade lesions, which otherwise might be upgraded 
(Dijkstra et al., 2010). Awareness of the different patterns of immunoreactivity might allow 
for a most proper use in certain clinicopathological settings. However, significant variability 
remains in the reported percentage of cases that stain positively for p16 and several 
unresolved technical issues remain, underlining the need for standardization of sample 
preparation and evaluation protocols (Mulvany et al., 2008; Tsoumpou et al., 2009). 
 
(a) (b) 
Fig. 1. (a,b). High-grade squamous intraepithelial lesion (HSIL-CIN2): (a) Hematoxylin and 
eosin staining, (b) p16 immunostain showing diffuse positivity. 
 
(a) (b) 
Fig. 2. (a,b). Low-grade squamous intraepithelial lesion: (a) Hematoxylin and eosin staining, 
(b) p16 immunostain showing focal positivity. 
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It is of note that: (a) in several studies, especially with increasing number of cases, there 
often appears a small group of HSILs that do not show any immunoreactivity, and (b) a 
significant percentage of LSILs associated with HR-HPV, as detected by PCR or HC2, does 
not exhibit p16 immunopositivity (Kostopoulou et al., 2011). The above observations lead to 
the conclusion that a negative or equivocal p16 immunostain should be carefully evaluated 
in conjunction with the histopathologic findings and should not be used as the main 
criterion for diagnosis. However, p16 may also be of use in evaluating cauterized cervical 
resection margins, since the positive staining pattern of HGSIL is not affected by diathermy 
in LLETZ biopsies (Dray et al., 2005). 
Finally, another aspect of p16 immunostaining is the possibility of correlation with lesion 
“progression”. It has been suggested that certain phases of a given HR-HPV-associated 
neoplastic process may have different indices of p16 expression (Keating et al., 2001). 
Although the detailed examination of this subject is not included in the aim of the present 
text, it should be mentioned that in an interesting study by Hariri and Oster (2007) 25/26 
low-grade lesions with negative p16 staining (concerning diffuse staining) and a minimum 
follow-up period of five years had a benign or normal outcome, revealing a negative 
predictive value of p16 in predicting the outcome of CIN 1 cases as high as 96%. In a study 
including conization specimens with coexisting CIN1 and CIN3 areas, all CIN1 were p16 
positive (Negri et al., 2008), while p16 staining did not predict persistence or clearance of 
HR-HPV after treatment for CIN in a study by Branca et al. (2004). 
 
 
(a) (b) 
Fig. 3. (a,b). Common patterns of p16 positivity in low-grade lesions 
2.2 Cyclins 
Cyclins have been reported to be of help in the evaluation of cervical biopsies. Cyclin E is 
uncommonly expressed in epithelia not infected by HPV and its conspicuous 
immunopositivity may facilitate the recognition of SIL (Keating et al., 2001). In addition, 
cyclin B1 immunoreactivity above the basal/parabasal cells correlates significantly with 
HPV detection and could be a marker of HPV presence (Kostopoulou et al., 2008a). Cyclins 
D and A have been also studied as possible markers of HPV-related lesions. 
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2.2.1 Cyclin B1 
It has been reported that E6/E7 oncoproteins of HPV type 18 induced changes in the 
expression of cell cycle regulatory proteins very early and before immortalization (Pei, 
1996). Significantly increased expression was noted for cyclin B and its transcriptional 
activation was documented. In 2000, Southern et al. demonstrated increased cyclin B1 
expression in HGSILs. In their study cyclin B protein was up-regulated and persisted into 
the upper epithelial layers in parallel with cyclin A expression in high-grade squamous 
intraepithelial lesions.  
In a study performed in our laboratory cyclin B1 immunostaining above the basal/parabasal 
layers was observed in all cases of HSIL (100%), most often involving the superficial layers 
as well (Kostopoulou et al., 2008a). Furthermore, increased cyclin B1 immunopositivity was 
observed in 51/52 low-grade lesions (98.07%) (Figure 4), and in seven of 15 biopsies (46.6%) 
characterized as atypia of unknown significance (AUS). Six of these seven cases tested HPV-
positive by PCR.  
 
(a) (b) 
Fig. 4. (a,b). Low grade squamous intraepithelial lesion: (a) Hematoxylin and eosin staining, 
(b) Cyclin B1 immunostain, showing sporadic positivity in mature squamous polygonal 
cells above the basal layers. 
The essential feature of the staining pattern observed in low-grade lesions and AUS cases in 
the above study consisted of sporadic cyclin B1 staining in mature squamous polygonal cells 
often just above the basal layers, with slight differences between flat and elevated lesions. 
This pattern of immunoreactivity was seen in 52 of 55 cases with HPV infection detected by 
PCR, whereas it was seen in only 5 cases without PCR-proven HPV infection. In 4 of the 
latter cases, however, p16 immunopositivity was detected, suggesting that HPV could be 
present though not detected by PCR. 
The pattern of immunoreactivity observed in low-grade lesions and AUS cases could be 
perceived as cytoplasmic accumulation or retention of cyclin B1 in suprabasal squamous cells. 
Several mechanisms could be related to this reaction (Kostopoulou et al., 2008a), while this 
pattern might reflect early events in the inhibition of G2-to-M transition, a well-known 
phenomenon during HPV infection in vitro. The possibility was suggested that these cyclin 
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B1-positive cells could be viewed as a type of ‘‘prekoilocytes”, whose eventual progression to 
koilocytes would depend on several parameters related to the intricacies of HPV infection. 
 
Fig. 5. Cyclin B1 positivity in an HSIL.  
In conclusion, cyclin B1 positivity above the basal/parabasal layers correlates significantly 
with HPV detection and could be a marker of HPV presence. Thus, it might constitute a 
helpful finding in difficult to diagnose cases. Immunopositivity in a specimen showing non-
diagnostic atypia should prompt reevaluation and/or HPV testing, as it is likely that the 
case could represent a genuine low-grade intraepithelial lesion. 
2.2.2 Cyclin E 
Cyclin E, another important cell cycle regulator, which promotes G1 transition, has been 
reported to exhibit increased expression in squamous intraepithelial lesions and invasive 
cervical carcinomas, although the exact mechanisms are not clear (Keating et al., 2001). 
In a study by Keating et al., (2001) moderate to strong immunopositivity for cyclin E was 
observed in 92.6% and in 91.6% of low-grade and high-grade intraepithelial lesions, 
respectively, being positive in 38/41 HR-HPV positive cases. Furthermore, in a group of 
nondiagnostic squamous atypias cyclin E positivity was associated with HPV positivity.  
In a study by Bahnassy et al. (2007), cyclin E staining increased from CIN1 to invasive 
carcinoma (16.7% to 88.4%, respectively), while gene amplification was detected in 11.1% of 
CIN1 cases and in 88.4% of carcinoma cases. 
In conclusion, although cyclin E staining is not useful in the distinction of low-grade from 
high-grade lesions, it could be used to discriminate reactive from neoplastic epithelium 
(Crum & Rose, 2006), especially in conjunction with other markers, as discussed in other 
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parts of the present text. As is the case with the other immunostains examined in this text, 
standardization of staining and evaluation protocols are important for the appropriate 
application of these markers in certain diagnostic dilemmas.   
2.3 Other proliferation/cell cycle markers 
2.3.1 Ki-67 
Ki-67, an antigen expressed in the nuclei of proliferating cells, has also been studied as an 
indicator of CIN. Ki-67 is expressed in the nucleus during the whole cell cycle, except for the 
G0 and G1 early phases. Although positivity is observed under normal conditions in the 
lower compartments of the multilayered squamous epithelium, staining of the middle and 
upper layers is indicative of an intraepithelial lesion (Figure 6).  
Immunopositivity for Ki-67 increases as a function of increasing lesion grade (Arafa et2008; 
Conesa-Zamora et al., 2009; Carreras et al., 2007; Keating et al., 2001; Mimica et al., 2010; Pinto 
et al., 2008), but immunostains should be interpreted with caution, since reactive and 
inflammatory lesions may result in increased epithelial proliferation. It is well-known to 
pathologists that reactive and reparative changes may pose a problem in the examination of 
proliferation markers and in the case of Ki-67 immunostaining positive nuclei may extend 
through most of the epithelium. However, Ki-67 immunostaining can be used as an adjunct 
to other markers, as already discussed. 
It should be noted that Ki-67 immunohistochemical stain may be especially helpful in 
differentiating atrophic epithelial changes from high-grade lesions (Crum & Rose, 2006). 
(a) (b) 
Fig. 6. (a,b). Ki-67positivity in (a) a low- and (b) a high-grade intraepithelial lesion. 
2.3.2 Aberrant S-phase 
Two relatively new biomarkers include the minichromosome maintenance protein 2 
(MCM2) and DNA topoisomerase IIa (TOP2A) (Pinto et al., 2008). These two proteins have a 
significant role in the regulation of DNA replication during S-phase. They are overexpressed 
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when S-phase induction is aberrant and have been shown to be overexpressed in CINs and 
cervical carcinomas (Badr et al., 2008; Pinto et al., 2008; Shi et al., 2007). TOP2A is a nuclear 
enzyme that regulates the enzymatic unlinking of DNA strands during chromosome 
replication. MCM2 functions also during DNA replication by loading the pre-replication 
complex onto DNA and unwinding the latter through helicase activity to permit synthesis. 
ProEx C (Tambouret et al., 2008) is a recently developed immunohistochemical assay that 
targets these two proteins and appears to be efficient in distinguishing reactive epithelial 
changes from squamous lesions, alone or in conjunction with p16. 
According to Shi et al. (2007), ProEXC is a better marker than p16 for the detection of LSILs, 
showing positivity in 94% of the cases in a series of 34 LSILs. In a study by Badr et al. (2008) 
strong positive staining for ProEx C involving the lower and upper halves of the epithelium 
was observed in 92% of high-grade squamous intraepithelial lesions. Condylomas and CIN I 
showed greater variability in patterns of staining, with immunopositivity extending into the 
upper half of the epithelium in 48% of cases.  
Pinto et al. (2008) included in their study cases with the differential diagnosis of HSIL vs 
reactive epithelial changes. ProEx C showed 87% sensitivity and 71% specificity for SIL in 
biopsy material. The authors reported a larger number of cells stained by ProEx C in 
comparison to MiB-1 in both HSIL and LSIL cases. In addition, the combination of p16 and 
ProEx C predicted more NoSIL (including normal, reactive, and/or atrophic epithelia) than 
p16 and MiB-1 (61% vs 43%). These observations suggested that ProEx C could be more 
useful in the distinction of reactive epithelial changes from SILs than MiB-1, providing a 
lower false positive rate relative to the latter. 
In a study by Sanati et al. (2010) sensitivity, specificity, positive and negative predictive 
value of ProExC in distinguishing high-grade squamous intraepithelial lesion from 
squamous metaplasia were 89%, 100%, 100%, and 82%, respectively. In a recent study by 
Guo et al., (2011) diffuse positivity for ProExC significantly increased from benign 
cervix/CIN 1 to CIN 2 or 3/carcinoma, while the highest specificity for CIN 2+ and CIN3+ 
(100% and 93%, respectively) was achieved when immunostaining was positive for both 
ProExC and p16, suggesting that it is advantageous to use these two markers together in 
order to distinguish high-grade lesions from their mimics. 
Walts and Bose (2009) suggested as cost saving strategy the use of two markers initially, p16 
and ProExC, followed by Ki-67 immunostaining in discordant cases. According to the above 
authors, performing the two above stains initially and adding Ki-67 only when p16 and 
ProExC yield discordant results provided the same diagnostic accuracy while reducing the 
cost, since only one third of the cases required performance of the third stain. 
2.4 Other markers and applications 
In the present text an effort has been made to cover the immunohistochemical markers, 
which are currently most useful from a diagnostic point of view, and have been evaluated in 
several studies and laboratories.  
In addition to the above biomarkers, which are in use in many pathology departments 
worldwide, a large number of other markers have been examined for their potential utility 
in the diagnosis and/or prognosis of cervical precursor lesions and in resolving problematic 
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cases (Galgano et al., 2010; Khan et al., 2008; Kostopoulou et al., 2008b). The results of these 
studies have been described in detail in the pertinent literature. In addition, image analysis 
methods have been used in an attempt to bring more objectivity to the interpretation of 
biopsy specimens. Furthermore, although the detection of SILs in cytology material and the 
evaluation of screening strategies are beyond the scope of the present text, it should be 
mentioned that the contribution of the above markers is important in this context, as 
presented in brief in the following (Carozzi et al., 2008; Depuydt et al., 2011; Tsoumpou et 
al., 2009). 
2.4.1 L1 capsid protein 
One recently studied marker, which has been examined repeatedly in cytologic material, is 
L1. Nuclear positivity for HPV L1 capsid protein, the major structural protein of human 
papillomavirus, is mainly observed in productive lesions and is gradually lost in high grade 
lesions and carcinomas.  
It has been suggested that combined L1/p16 immunostaining may be helpful for clinical 
management, especially in cases in which the grade of the lesion is difficult to assess (Negri 
et al., 2008). 
In a study by Galgano et al. (2010), this protein, which should be highly correlated with a 
productive viral infection, was neither sensitive nor specific for any group of cervical 
neoplasia in biopsy material. This was attributed to the complexity of the temporal 
evolution of the HPV virion production which may be quite transient. It is interesting that 
L1 positive cases with a negative consensus diagnosis in this study had commonly at least 1 
reviewer diagnosis of CIN1, revealing once again the difficulties in the distinction of SIL vs 
negative for SIL and the importance of a panel of immunostains in this specific context. 
2.4.2 In situ hybridization techniques 
Detection of papillomavirus nucleic acids is currently performed by methods that can be 
broadly subdivided into methods based on target amplification and those based on signal 
amplification (Snijders et al., 2010). In addition to several existing liquid phase techniques, 
in situ hybridization (ISH) methods have been developed for cytological and histological 
specimens. Both fluorescent detection and coloured substrate deposition followed by bright-
field microscopy can be used, and can be combined with tyramide signal amplification. ISH 
assays can also be automated along the same lines as immunohistochemistry. Finally, except 
for HPV nucleic acids, other applications of in situ hybridization include the detection of 
amplification of the gene coding for the telomerase RNA component (TERC) at 3q26 
(Hopman et al., 2006; Zheng et al., 2010). 
Issues concerning sensitivity of the above techniques in comparison to PCR have been 
repeatedly raised. However, ISH techniques are becoming increasingly sensitive and can 
now detect low copy numbers of HPV DNA (Kelesidis et al., 2011; Montag et al., 2011). In 
addition, their important contribution to HPV research is the fact that they allow concurrent 
morphological evaluation of the areas examined, mainly in the case of histological 
specimens. Furthermore, the signal patterns observed in HPV ISH have been reported to be 
associated with the physical status of viral DNA in the cells examined, that is episomal or 
integrated. Specifically, the punctate pattern of positivity has been linked to the presence of 
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integrated viral forms in the host genome (Cooper et al., 1991; Evans et al., 2002; Hopman et 
al., 2005).  
In a study by Guo et al. (2008) ISH and PCR had fair to good agreement in detecting HPV 
DNA across CIN categories, but ISH detected significantly fewer HPV-positive cases in 
carcinomas than PCR did, probably as a result of lower copy numbers of episomal as 
compared to integrated HPV DNA in the latter. In addition, although the pure punctate 
pattern of HPV indicated a high level of viral integration, the level of HPV integration could 
not be accurately determined in cases with mixed signal patterns, probably due to a 
variation in the percentage of the two patterns in these cases. Recently, Ho et al. (2011) 
reported a punctate pattern in 8.7% of CIN1 lesions vs 34.0% of CIN3 lesions in cytology 
material, while Alameda et al. (2011) reported a correlation of the punctate pattern with 
lesion persistence in cytology specimens. 
According to Kong et al. (2007), in cases of atypical squamous metaplasia, p16 reactivity 
(focal strong and diffuse strong) was significantly more sensitive than ISH in correlating 
with the presence of human papillomavirus as detected by polymerase chain reaction. In a 
more recent study by Kelesidis et al. (2011), ISH exhibited a sensitivity of 89.5% for the 
detection of CIN2+ lesions, while PCR showed sensitivity of 94.7% for these lesions. A 
percentage of ISH-positive cases was not detected by PCR (performed on liquid-based 
sample media), emphasizing the technical problems and limitations of the techniques.  
Voss et al. (2009) compared a fluorescence in situ hybridization (FISH) HR-HPV assay to 
Hybrid Capture 2 (HC2) and polymerase chain reaction (PCR) for the detection of HR-HPV 
subtypes in cervical cytology specimens. FISH was concordant with HC2 and PCR in 85% 
and 82% of the specimens, respectively, while HC2 and PCR were concordant in 84% of the 
specimens.  
It is apparent from the above results that the applications of HPV ISH are partly dependent 
on the sensitivity of the assay and its sufficiency to carry a high negative predictive value 
(Crum & Rose 2006). This is especially important if clinical decisions are based on a negative 
result. However, ISH represents a useful tool for ancillary molecular HPV testing in cervical 
specimens, and may be important in certain clinicopathologic situations.  
2.4.3 Applications in cytology 
The preceding text focused mainly on the application of immunohistochemistry in SIL 
diagnosis in histopathology specimens. However, several of the above markers have been 
applied in cytopathology material, as presented in brief in the following paragraphs. The 
introduction of liquid-based techniques, which has been one of the most important advances 
in this field, has facilitated relevant applications. 
The most studied marker in cytology is p16. Positivity has been observed in 10%-86% of 
LSIL and in 42%-100% of HSIL, as reviewed by Tsoumpou et al. (2009). The lack of general 
consensus regarding threshold values for p16 positivity is especially important in cervical 
cytology specimens. Several authors have used both quantitative and qualitative criteria, 
evaluating the number of positive cells as well as cell morphology, recognizing the fact that 
p16 overexpression may be often detected in nondysplastic cells. In the contrary, other 
investigators used only quantitative criteria. 
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It has been suggested that p16 immunocytochemical testing can be used as a reflex test in 
conjunction with liquid-based cytology following a cytologic result of ASC-US or LSIL, or be 
used on destained conventional or liquid-based cytology specimens (Denton et al., 2010). 
p16 in conjunction with Ki-67 provide high sensitivity for the detection of CIN2+ lesions 
(Schmidt et al., 2011; Yu et al., 2010). 
The prognostic utility of L1 immunocytochemistry, especially in association with p16 in 
cytology, has been reported by several authors (Griesser et al., 2004; Sarmadi et al., 2011; 
Yoshida et al., 2008). 
The use of HPV in situ hybridization has already been discussed in the previous section. It is 
of note that, in a recent study, prior knowledge of HPV status resulted in significantly 
higher detection rate of CIN2+ in cytology specimens compared to screening blinded to 
HPV status, with limited loss of specificity (Benoy et al., 2011). This raises several important 
questions, although more research is needed to study the significance of this type of 
knowledge provided prior to cytological reading. 
3. Conclusion 
Although histopathology remains the ‘‘gold standard’’ for the diagnosis of SIL, both low- 
and high-grade, certain biomarkers have emerged as helpful adjuncts. Their combined use 
may assist in the histopathologic classification of preinvasive lesions and facilitate the 
distinction from non-HPV induced alterations. It is clear from the above that the diagnosis 
of a squamous intraepithelial lesion in a diagnostically challenging case cannot at present be 
based solely on any particular marker, but rather on a combination of markers with careful 
morphological evaluation, the latter comprising the most important part of the diagnostic 
procedure. Standardization of protocols and familiarity with the patterns of 
immunostaining, especially in nonneoplastic cervical tissue, are important requirements for 
the proper use of the above markers. Awareness of the strengths and limitations of each 
particular technique cannot be overemphasized. In addition, the performance of several 
markers and methods in the detection of lesions related to HPV types other than those 
addressed by the current vaccines remains to be carefully evaluated. 
4. References 
Agoff, SN., Lin, P., Morihara, J., Mao, C., Kiviat, N.B. & Koutsky, L.A. (2003). p 16(INK4a) 
expression correlates with degree of cervical neoplasia: a comparison with Ki-67 
expression and detection of high-risk HPV types. Modern Pathology, Vol.16, pp.665-
673 
Alameda, F., Mariñoso, M.L., Bellosillo, B., Muset, M., Pairet, S., Soler, I., Romero, E., 
Larrazabal, F., Carreras, R. & Serrano, S. (2011). Detection of HPV by in situ 
hybridization in thin-layer (ThinPrep) cervicovaginal samples. Tumour Biology, 
Vol.32, No.3, pp.603-609, Epub 2011 Feb 8 
Andersson, S., Hansson, B., Norman, I., Gaberi, V., Mints, M., Hjerpe, A., et al. (2006). 
Expression of E6/E7 mRNA from 'high risk' human papillomavirus in relation to 
www.intechopen.com
Human Papillomavirus and Related Diseases  
– From Bench to Bedside – A Clinical Perspective 
 
56
CIN grade, viral load and p16INK4a. International Journal of Oncology, Vol. 29, No.3, 
pp. 705-711 
Arafa, M., Boniver, J & Delvenne P. (2008). Detection of HPV-induced cervical (pre) 
neoplastic lesions: a tissue microarray (TMA) study. Applied Immunohistochemistry 
and Molecular Morphology, Vol.16, No.5, pp.422-432 
Badr, R.E., Walts, A.E., Chung, F. & Bose, S. (2008). BD ProEx C: a sensitive and specific 
marker of HPV-associated squamous lesions of the cervix. American Journal of 
Surgical Pathology, Vol.32, pp.899-906 
Bahnassy, A., Zekri, A., Saleh, M., Lotayef, M., Moneir, M. & Shawki, O. (2007). The possible 
role of cell cycle regulators in multistep process of HPV-associated cervical 
carcinoma. BMC Clinical Pathology, Vol.7, pp.4 
Benoy, I., Vanden Broeck, D., Ruymbeke, M., Sahebali, S., Arbyn, M., Bogers, J., 
Temmerman, M. & Depuydt, C. Prior knowledge of HPV status improves detection 
of CIN2+ by cytology screening. American Journal of Obstetrics and Gynecology, in 
press. 
Bergeron, C., Ordi, J., Schmidt, D., Trunk, M., Keller, T. & Ridder, R., for the European 
CINtec Histology Study Group. (2010). Conjunctive p16INK4a Testing Significantly 
Increases Accuracy in Diagnosing High-Grade Cervical Intraepithelial Neoplasia. 
American Journal of Clinical Pathology, Vol.133, pp.395-406 
Bergonzini, V., Salata, C., Calistri, A., Parolin, C. & Palu, G. (2010). View and review on viral 
oncology research. Infectious Agents and Cancer, Vol.5:, pp.11 
Bogaards, J.A., Coupé, V.M., Xiridou, M., Meijer, C.J., Wallinga, J. & Berkhof, J. (2011). Long-
term Impact of Human Papillomavirus Vaccination on Infection Rates, Cervical 
Abnormalities, and Cancer Incidence. Epidemiology, Vol.22, No.4, pp.505-515 
Bollmann, M., Bankfalvi, A., Trosic, A., Speich, N., Schmitt, C. & Bollmann, R. (2005). Can 
we detect cervical human papillomavirus (HPV) infection by cytomorphology 
alone? Diagnostic value of non-classic cytological signs of HPV effect in minimally 
abnormal Pap tests. Cytopathology, Vol.16, pp.13–21 
Bosch, F.X., Lorincz, A., Munoz, N., Meijer, C.J. & Shah, K.V. (2002). The causal relation 
between human papillomavirus and cervical cancer. Journal of Clinical Pathology., 
Vol.55, pp.244-265  
Bosch, F.X., Qiao, Y. & Castellsague, X. (2006). The epidemiology of human papillomavirus 
infection and its association with cervical cancer. International Journal of Gynecology 
and Obstetrics, Vol.94(Supplement 1), pp.S8---S21 
Branca, M., Ciotti, M., Santini, D., Di Bonito, L., Giorgi, C., Benedetto, A., et al. (2004). 
p16INK4a expression is related to grade of CIN and high-risk human papillomavirus 
but does not predict virus clearance after conization or disease outcome. 
International Journal of Gynecological Pathology, Vol. 23, pp.354-365  
Carozzi, F., Confortini, M., Dalla Palma, P., Del Mistro, A., Gillio-Tos, A., De Marco, L., 
Giorgi-Rossi, P., Pontenani, G., Rosso, S., Sani, C., Sintoni, C., Segnan, N., Zorzi, M., 
Cuzick, J., Rizzolo, R., Ronco, G.; New Technologies for Cervival Cancer Screening 
(NTCC) Working Group. (2008). Use of p16-INK4A overexpression to increase the 
specificity of human papillomavirus testing: a nested substudy of the NTCC 
randomised controlled trial. Lancet Oncology, Vol.9, No.10, pp.937-945, Epub 2008 
Sep 8. 
www.intechopen.com
 
Immunohistochemistry in the Diagnosis of Squamous Intraepithelial Lesions of the Uterine Cervix 
 
57 
Carreras, R., Alameda, F., Mancebo, G., García-Moreno, P., Mariñoso, M.L., Costa, C., Fusté, 
P., Baró, T. & Serrano, S. (2007). A study of Ki-67, c-erbB2 and cyclin D-1 expression 
in CIN-I, CIN-III and squamous cell carcinoma of the cervix. Histology and 
Histopathology, Vol.22, No.6, pp.587-592 
Cho, N.H., Kang, S., Hong, S., Jeong, G.B., Choi, I.W., Choi, H.J. & Choi, H.K. (2005). 
Multinucleation of koilocytes is in fact multilobation and is related to aberration of 
the G2 checkpoint. Journal of Clinical Pathology, Vol.58, pp.576–582 
Clifford, G.M., Smith, J.S., Plummer, M., Munoz, N. & Franceschi, S. (2003). Human 
papillomavirus types in invasive cervical cancer worldwide: a metaanalysis. British 
Journal of Cancer, Vol.88, No.1, pp.63–73  
Cohen, J.A. & Geradts, J. (1997). Loss of Rb and MTS1/CDKN2 (P16) expression in human 
sarcomas. Human Pathology, Vol.28, pp.893–898  
Collins, S., Rollason, T., Young, L. & Woodman C. (2010). Cigarette smoking is an 
independent risk factor for cervical intraepithelial neoplasia in young women: A 
longitudinal study. European Journal of Cancer, Vol. 46, No.2, pp.405–411 
Conesa-Zamora, P., Domenech-Peris, A., Orantes-Casado, F.,  Ortiz-Reina, S., Sahuquillo-
Frias, L., Acosta-Ortega, J., Garcia-Solano, J. & Perez-Guillermo, M. (2009). Effect of 
Human Papillomavirus on Cell Cycle–Related Proteins p16, Ki-67, Cyclin D1, p53, 
and ProEx C in Precursor Lesions of Cervical Carcinoma. American Journal of 
Clinical Pathology, Vol.132, pp.378-390 
Cooper, K., Herrington, C.S., Stickland, J.E., Evans, M.F. & McGee J.O.. (1991). Episomal and 
integrated human papillomavirus in cervical neoplasia shown by non-isotopic in 
situ hybridization. Journal of Clinical Pathology, Vol.44, pp.990–996 
Crum, C.P., Ikenberg, H., Richart, R.M. & Gissmann, L. (1984). Human papillomavirus type 
16 and early cervical neoplasia. New England Journal of Medicine, Vol.310, pp.880–
883 
Crum, C.P. Contemporary theories of cervical carcinogenesis: the virus, the host, and the 
stem cell. (2000). Modern Pathology, Vol.13, pp.243–251 
Crum, C.P., Abbott, D.W. & Quade, B.J. (2003). Cervical cancer screening: from the 
Papanicolaou smear to the vaccine era. Journal of Clinical Oncology, Vol. 21(10 
Suppl), pp.224–230 
Crum, C.P. & Rose, P. (2006). Cervical squamous neoplasia. In: Diagnostic Gynecologic and 
Obstetric Pathology. C.P. Crum & K.R. Lee, (Eds.), 267-354, Elsevier 
Cuzick, J., Mayrand, M., Ronco, G., Snijders, P. & Wardle, J. (2006). Chapter 10: New 
dimensions in cervical cancer screening. Vaccine, Vol.24(S3), pp.S90-97 
Denton, K., Bergeron, C., Klement, P., Trunk, M., Keller, T. & Ridder, R., for the European 
CINtec Cytology Study Group. (2010). The Sensitivity and Specificity of p16INK4a 
Cytology vs HPV Testing for Detecting High-Grade Cervical Disease in the Triage 
of ASC-US and LSIL Pap Cytology Results. American Journal of Clinical Pathology, 
Vol.134, pp.12-21 
Depuydt, C.E., Makar, A.P., Ruymbeke, M.J., Benoy, I.H., Vereecken, A.J. & Bogers, J.J. 
(2011). BD-ProExC as adjunct molecular marker for improved detection of CIN2+ 
after HPV primary screening. Cancer Epidemiology, Biomarkers and Prevention, Vol.20, 
No.4, pp.628-637, Epub 2011 Feb 4 
Dijkstra, M.G., Heideman, D.A., de Roy, S.C., Rozendaal, L., Berkhof, J., van Krimpen, K., 
van Groningen, K., Snijders, P.J., Meijer, C.J. & van Kemenade, F.J. (2010). 
www.intechopen.com
Human Papillomavirus and Related Diseases  
– From Bench to Bedside – A Clinical Perspective 
 
58
p16(INK4a) immunostaining as an alternative to histology review for reliable 
grading of cervical intraepithelial lesions. Journal of Clinical Pathology, Vol.63(, 
No.11, pp.972-927, Epub 2010 Oct 5 
Dray, M., Russell, P., Dalrymple, C., Wallman, N., Angus, G., Leong, A. et al. (2005). p16INK4a 
as a complementary marker of high-grade intraepithelial lesions of the uterine 
cervix. I: Experience with squamous lesions in 189 consecutive cervical biopsies. 
Pathology, Vol. 37, No.2, pp.112–124 
Duensing, S., Lee, L.Y., Duensing, A., Basile, J., Piboonniyom, S., Gonzalez, S., Crum, C.P. & 
Munger, K. (2000). The human papillomavirus type 16 E6 and E7 oncoproteins 
cooperate to induce mitotic defects and genomic instability by uncoupling 
centrosome duplication from the cell division cycle. Proceedings of the National 
Academy of Sciences, Vol.97, pp.10002–10007  
Evans, M.F., Mount, S.L., Beatty, B.G. & Cooper, K. (2002). Biotinyltyramide-based in situ 
hybridization signal patterns distinguish human papillomavirus type and grade of 
cervical intraepithelial neoplasia. Modern Pathology,Vol.15, pp.1339–1347  
Focchi, G., Silva, I., Nogueira-de-Souza, N., Dobo, C., Oshima, C. & Stavale, J. (2007).  
Immunohistochemical Expression of p16(INK4A) in Normal Uterine Cervix, 
Nonneoplastic Epithelial Lesions, and Low-grade Squamous Intraepithelial 
Lesions. Journal of Lower Genital Tract Disease, Vol.11, pp.98-104 
Frazer, I. (2009). Interaction of human papillomaviruses with the host immune system: A 
well evolved relationship. Virology, Vol.384, pp.410–414 
Fuste, V., del Pino, M., Perez, A., Garcia, A., Torne, A., Pahisa, J. & Ordi, J. (2010). Primary 
squamous cell carcinoma of the vagina: human papillomavirus detection, 
p16INK4A overexpression and clinicopathological correlations. Histopathology, 
Vol.57, pp.907–916 
Giarrè, M., Caldeira, S., Malanchi, I., Ciccolini, F., Leão, M.J. & Tommasino, M. (2001). 
Induction of pRb degradation by the human papillomavirus type 16 E7 protein is 
essential to efficiently overcome p16INK4a-imposed G1 cell cycle arrest. Journal of 
Virology, Vol. 75, No.10, pp.4705-4712 
Godoy, A., Mandelli, J., Oliveira, F., Calegari, S., Moura, L. & Serafini, E. (2008). p16INK4 
expression in precursor lesions of squamous cell cervical cancer related to the 
presence of HPV-DNA. Brazilian Journal of Medical and Biological Research, Vol.41, 
pp.583-588 
Gravitt, P.E., Coutlιe, F., Iftner, T., Sellors, J.W., Quint, W.G. & Wheeler, C.M. (2008). New 
technologies in cervical cancer screening. Vaccine, Vol.26, No.Suppl.10, pp.42-52  
Griesser, H., Sander, H., Hilfrich, R., Moser, B. & Schenck U. (2004). Correlation of 
immunochemical detection of HPV L1 capsid protein in pap smears with 
regression of high-risk HPV positive mild/moderate dysplasia. Analytical and 
Quantitative Cytology and Histology, Vol.26, No.5, pp.241-245 
Gross, G. & Pfister, H. (2004). Role of human papillomavirus in penile cancer, penile 
intraepithelial squamous cell neoplasias and in genital warts. Medical Microbiology 
and Immunology, Vol.193:, pp.35–44 
Guillaud, M., Adler-Storthz, K., Malpica, A., Staerkel, G., Matisic, J., Van Niekirk, D., Cox, 
D., Poulin, N., Follen, M. & MacAulay, C. (2005). Subvisual chromatin changes in 
cervical epithelium measured by texture image analysis and correlated with HPV. 
Gynecologic Oncology, Vol.99, No.3suppl 1), pp.16–23 
www.intechopen.com
 
Immunohistochemistry in the Diagnosis of Squamous Intraepithelial Lesions of the Uterine Cervix 
 
59 
Guo, M., Baruch, A.C., Silva, E.G., Jan, Y.J., Lin, E., Sneige, N. & Deavers M.T. (2011). 
Efficacy of p16 and ProExC immunostaining in the detection of high-grade cervical 
intraepithelial neoplasia and cervical carcinoma.  American Journal of Clinical 
Pathology, Vol.135, No.2, pp.212-220 
Guo, M., Gong, Y., Deavers, M., Silva, E.G., Jan, Y.J., Cogdell, D.E., Luthra, R., Lin, E., Lai, 
H.C., Zhang, W. & Sneige, N. (2008). Evaluation of a commercialized in situ 
hybridization assay for detecting human papillomavirus DNA in tissue specimens 
from patients with cervical intraepithelial neoplasia and cervical carcinoma. Journal 
of Clinical Microbiology, Vol.46, No.1, pp.274-280, Epub 2007 Oct 31 
Hariri, J. & Oster, A. (2007). The Negative Predictive Value of p16INK4a to Assess the 
Outcome of Cervical Intraepithelial Neoplasia 1 in the Uterine Cervix. International 
Journal of Gynecological Pathology, Vol.26, pp.223–228  
Ho, C.M., Lee, B.H., Chang, S.F., Chien, T.Y., Huang S.H., Yan, C.C. & Cheng, W.F. (2011). 
Clinical significance of signal pattern of high-risk human papillomavirus using a 
novel fluorescence in situ hybridization assay in cervical cytology. Clinical 
Microbiology and Infection, Vol.17, No.3, pp.386-394 
Hopman, A. H., Kamps, M. A., Smedts, F., Speel E. J., Herrington, C. S., & Ramaekers, F. C.. 
(2005). HPV in situ hybridization: impact of different protocols on the detection of 
integrated HPV. International Journal of Cancer, Vol.115, pp.419–428 
Hopman, A.H.,Theelen, W., Hommelberg, P.P., Kamps, M.A., Herrington, C.S.,  Morrison, 
L.E., Speel, E.J., Smedts, F. & Ramaekers, F.C. (2006). Genomic integration of 
oncogenic HPV and gain of the human telomerase gene TERC at 3q26 are strongly 
associated events in the progression of uterine cervical dysplasia to invasive cancer. 
Journal of Pathology, Vol.210, No.4, pp.412-419 
Horn, L., Reichert, A., Oster, A., Arndal, S., Trunk, M., Ridder, R., et al. (2008). 
Immunostaining for p16INK4a Used as a Conjunctive Tool Improves Interobserver 
Agreement of the Histologic Diagnosis of Cervical Intraepithelial Neoplasia. 
American Journal of Surgical Pathology, Vol. 32, pp.502–12 
Hu, L., Plafker, K., Vorozhoko, V., Zuna, R., Hanigan, M., Gorbsky, G., Plafker, S., Angeletti, 
P. & Ceresa, B. (2009). Human Papillomavirus 16 E5 Induces Bi-Nucleated Cell 
Formation By Cell-Cell Fusion. Virology, Vol.384, No.1, pp.125–134 
Insinga, R., Liaw, K., Johnson, L., & Madeleine, M. (2008). A Systematic Review of the 
Prevalence and Attribution of Human Papillomavirus Types Among Cervical, 
Vaginal and Vulvar Precancers and Cancers in the United States. Cancer 
Epidemiology Biomarkers and Prevention. Vol. 17, No.7, pp.1611–1622 
Ishikawa, M., Fujii, T., Saito, M., Nindl, I., Ono, A., Kubushiro, K., et al. (2006). 
Overexpression of p16INK4a as an indicator for human papillomavirus oncogenic 
activity in cervical squamous neoplasia.  International Journal of Gynecological Cancer, 
Vol.16, No.1, pp.347–353 
Kalof, A.N., Evans, M.F., Simmons-Arnold, L., Beatty, B. & Kumarasen, C. (2005). p16INK4A 
immunoexpression and HPV in situ hybridization signal patterns: potential 
markers of high-grade cervical intraepithelial neoplasia. American Journal of Surgical 
Pathology, Vol.29, pp.674–679 
Keating, J.T., Cviko, A., Riethdorf, S., Riethdorf, L., Quade, B.J., Sun, D., et al. (2001). Ki-67, 
cyclin E, and p16INK4 are complimentary surrogate biomarkers for human 
www.intechopen.com
Human Papillomavirus and Related Diseases  
– From Bench to Bedside – A Clinical Perspective 
 
60
papilloma virus-related cervical neoplasia. American Journal of Surgical Pathology, 
Vol. 25, pp.884–891 
Kelesidis, T., Aish, L., Steller, M.A., Aish, I.S., Shen, J., Foukas, P., Panayiotides, J., Petrikkos, 
G., Karakitsos, P. & Tsiodras, S. (2011). Human Papillomavirus (HPV) Detection 
Using In Situ Hybridization in Histologic Samples: Correlations With Cytologic 
Changes and Polymerase Chain Reaction HPV Detection.  American Journal of 
Clinical Pathology, Vol.136, No.1, pp.119-127 
Khan, A.M. & Singer, A. (2008). Biomarkers in cervical precancer management: the new 
frontiers. Future Oncology, Vol.4, No.4, pp.515-524 
Kong, C.S., Balzer, B.L., Troxell, M.L., Patterson, B.K. & Longacre, T.A. (2007). p16INK4A 
immunohistochemistry is superior to HPV in situ hybridization for the detection of 
high-risk HPV in atypical squamous metaplasia. American Journal of Surgical 
Pathology, Vol.31, No.1, pp.33-43 
Kostopoulou, E., Keating, J.T. & Crum, C.P. (2001). Pathology. In: American Cancer Society 
Atlas of Clinical Oncology. Cancer of the female lower genital tract. P.J. Eifel, C. 
Levenback, (Eds), 9-36, BC Decker, Hamilton, London  
Kostopoulou, E., Samara, M., Kollia, P., Zacharouli, K., Mademtzis, I., Daponte, A., Messinis, 
I.E. &, Koukoulis, G. (2008a). Correlation Between Cyclin B1 Immunostaining in 
Cervical Biopsies and HPV Detection by PCR. Applied Immunohistochemistry and 
Molecular Morphology, Vol.17, No.2, pp.115-120, Epub Oct 28; 2008a. 
Kostopoulou, E., Samara, M., Kollia, P., Zacharouli, K.& Koukoulis, G. (2008b). INCENP, 
cyclin B1 and ERK1 immunopositivity in cervical biopsies. Histopathology, Vol.53, 
No.438Sp.Iss., pp.192-193  
Kostopoulou, E., Samara, M., Kollia, P., Zacharouli, K., Mademtzis, I., Daponte, A., Messinis, 
I.E. & Koukoulis, G. (2011). Different patterns of p16 immunoreactivity in cervical 
biopsies: Correlation to lesion grade and HPV detection, with review of the 
literature. European Journal of Gynaecological Oncology, Vol.32, No.1, pp.54-61 
Kurman, R., Norris, H. & Wilkinson, E. (1992). Tumors of the cervix, vagina and vulva. A.F.I.P. 
Atlas of tumor Pathology, 3rd series. A.F.I.P., Washington 
Louie, K.S., Castellsague, X., de Sanjose, S., Herrero, R., Meijer, C.J., Shah, K., Munoz, N., 
Bosch, F.X.; for the International Agency for Research on Cancer Multicenter 
Cervical Cancer Study Group. (2011). Smoking and Passive Smoking in Cervical 
Cancer Risk: Pooled Analysis of Couples from the IARC Multicentric Case-Control 
Studies. Cancer Epidemiology, Biomarkers and Prevention. Vol.20, No.7, pp.1379-1390, 
Epub 2011 May 24. 
Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., et al. (1995). 
Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor 
p16. Nature, Vol.375, pp.503–506 
McLaughlin-Drubin, M. & Münger, K. (2009a). The Human Papillomavirus E7 Oncoprotein. 
Virology, Vol.384, No.2, pp.335–344  
McLaughlin-Drubin, M. & Münger, K. (2009b). Oncogenic Activities of Human 
Papillomaviruses. Virus Research, Vol.143, No.2, pp. 195–208 
Mimica, M., Tomić, S., Kardum, G., Hofman, I.D., Kaliterna, V. & Pejković, L. (2010). Ki-67 
quantitative evaluation as a marker of cervical intraepithelial neoplasia and human 
papillomavirus infection. International Journal of Gynecological Cancer, Vol.20, No.1, 
pp.116-119 
www.intechopen.com
 
Immunohistochemistry in the Diagnosis of Squamous Intraepithelial Lesions of the Uterine Cervix 
 
61 
Montag, M., Blankenstein, T., Shabani, N., Bru¨ning, A. & Mylonas, I. (2011) Evaluation of 
two commercialised in situ hybridisation assays for detecting HPV-DNA in 
formalin-fixed, paraffin-embedded Tissue. Archives of Gynecology and Obstetrics, 
Vol.284, pp.999–1005 
Moscicki, A., Schiffman, M., Kjaer, S. & Villa, L. (2006) Chapter 5: Updating the natural 
history of HPV and anogenital cancer. Vaccine, Vol.24, No.S3, pp.42-51 
Mulvany, N.J., Allen, D.G.& Wilson, S.M. (2008). Diagnostic utility of p16INK4a: a 
reappraisal of its use in cervical biopsies. Pathology, Vol.40, No.4, pp.335-344 
Münger, K., Yee, C.L., Phelps, W.C., Pietenpol, J.A., Moses, H.L. & Howley, P.M. (1991). 
Biochemical and biological differences between E7 oncoproteins of the high- and 
low risk human papillomavirus types are determined by amino-terminal 
sequences. Journal of Virology, Vol.65, pp.3943–3948 
Munoz, N., Bosch, F.X., de Sanjose, S., Herrero, R., Castellsague, X., Shah, K.V., et al. (2003). 
Epidemiologic classification of human papillomavirus types associated with 
cervical cancer. New England Journal of Medicine, Vol.348, pp.518–527 
Munoz, N., Castellsague, X., Berrington de Gonzalez, A. & Gissmann, L. (2006) Chapter 1: 
HPV in the etiology of human cancer. Vaccine, Vol.24, No.S3, pp.1-10 
Murphy, N., Ring, M., Hefron, C.C., King, B., Killalea, A., Hughes, C., et al. (2005). 
p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive 
neoplasia and cervical cancer. Journal of Clinical Pathology, Vol.58, pp.525–534  
Nakao, Y., Yang, X., Yokoyama, M., Ferenczy, A., Tang, S.C., Pater, M.M., et al. (1997). 
Induction of p16 during immortalization by HPV 16 and 18 and not during 
malignant transformation. British Journal of Cancer, Vol.75, No.10, pp.1410-1416 
Nakashima, R., Fujita, M., Enomoto, T., Haba, T., Yoshino, K., Wada, H., et al. (1999). 
Alteration of p16 and p15 genes in human uterine tumours. British Journal of Cancer, 
Vol.80, pp.458-467  
Negri, G., Vittadello, F., Romano, F., Kasal, A., Rivasi, F., Girlando, S., et al. (2004). 
P16INK4a expression and progression risk of low-grade intraepithelial neoplasia of 
the cervix uteri. Virchows Archives, Vol.445, pp.616–20 
Negri, G., Bellisano, G., Zannoni, G.F., Rivasi, F., Kasal, A., Vittadello, F., et al. (2008). 
P16ink4a and HPV L1 immunohistochemistry is helpful for estimating the behavior 
of low-grade dysplastic lesions of the cervix uterii. American Journal of Surgical 
Pathology,  Vol.32, No.11, pp.1715-1720 
O’Neill, C. & McCluggage, G. (2006). p16 expression in the female genital tract and its value 
in diagnosis. Advances in Anatomic Pathology, Vol.13, pp.8–15 
Ohtani, N., Yamakoshi, K., Takahashi, A. & Hara, E. (2004). The p16INK4A-RB pathway: 
molecular link between cellular senescence and tumor suppression. Journal of 
Medical Investigation, Vol.51, pp.146-153 
Ordi, J., Garcia, S., del Pino, M., Landol, S., Alonso, I., Quinto,΄ L., & Torne,΄ A. (2008). 
p16INK4a immunostaining identifies occult CIN lesions in HPV-positive women. 
International Journal of Gynecological Pathology, Vol.28, pp.90–97 
Pei, X.F. (1996). The human papillomavirus E6/E7 genes induce discordant changes in the 
expression of cell growth regulatory proteins. Carcinogenesis, Vol.17, pp.1395–1401 
Pett, M. & Coleman, N. (2007). Integration of high-risk human papillomavirus: a key event 
in cervical carcinogenesis? Journal of Pathology, Vol.212:, pp.356–367 
www.intechopen.com
Human Papillomavirus and Related Diseases  
– From Bench to Bedside – A Clinical Perspective 
 
62
Pinto, A., Schlecht, N., Woo, T., Crum, C.P. & Cibas, E. (2008). Biomarker (ProEx C, 
p16INK4A, and MiB-1) distinction of high-grade squamous intraepithelial lesion 
from its mimics. Modern Pathology, Vol.21, pp.1067–1074 
Poljak, M. & Kocjan, B. (2010) Commercially available assays for multiplex detection of 
alpha human papillomaviruses Expert Rev. Anti Infect Therapy, Vol.8, No.10, 
pp.1139–1162  
Prasad, C., Genest, D. & Crum, C.P. (1994). Nondiagnostic squamous atypia of the cervix 
(atypical squamous epithelium of undetermined significance): histologic and 
molecular correlates. International Journal of Gynecological Pathology, Vol.13, pp.220–
227  
Quelle, D., Zindy, F., Ashmund, R. & Sherr, C.J. (1995). Alternative reading frames of the 
INK4α tumor suppressor gene encode two unrelated proteins capable of inducing 
cell cycle arrest. Cell, Vol.83, pp.993-1000  
Ruas, M. & Peters, G. (1998). The p16INK4a/CDKN2A tumor suppressor and its relatives. 
Biochimica et Biophysica Acta, Vol.1378, pp.115-177 
Salvia, P., Bergo, S., Bonesso-Sabadini, P., Tagliarini, E., Hackel, C. & De Angelo Andrade, L. 
(2004). Correlation between histological criteria and human papillomavirus 
presence based on PCR assay in cervical biopsies. International Journal of 
Gynecological Cancer, Vol.14, pp.126–132 
Sanati, S., Huettner, P. & Ylagan, L.R. (2010). Role of ProExC: a novel immunoperoxidase 
marker in the evaluation of dysplastic squamous and glandular lesions in cervical 
specimens. International Journal of Gynecological Pathology, Vol.29, No.1, pp.79-87 
Sano, T., Oyama, T., Kashiwabara, K., Fukuda, T. & Nakajima, T. (1998). Expression status of 
p16 protein is associated with human papillomavirus oncogenic potential in 
cervical and genital lesions American Journal of Pathology, Vol.153, pp.1741–1748  
Sarmadi, S., Izadi-Mood, N., Pourlashkari, M., Yarandi, F. & Sanii, S. (2011). HPV L1 capsid 
protein expression in squamous intraepithelial lesions of cervix uteri and its 
relevance to disease outcome. Archives of Gynecology and Obstetrics, Jul 26. [Epub 
ahead of print] 
Scheffner, M., Werness, B.A., Huibregtse, J.M., Levine, A.J. & Howley, P.M. (1990). The E6 
oncoprotein encoded by human papillomavirus types 16 and 18 promotes the 
degradation of p53. Cell, Vol.63, pp.1129–1136 
Scheurer, M.E., Guillaud, M., Tortolero-Luna, G., McAulay, C., Follen, M. & Adler-Storthz, 
K.(2007). Human papillomavirus-related cellular changes measured by cytometric 
analysis of DNA ploidy and chromatin texture. Cytometry B Clinical Cytometry, 
Vol.72, pp.324–331 
Schmidt, D., Bergeron, C., Denton, K.J., Ridder, R.; European CINtec Cytology Study Group. 
(2011). p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL 
papanicolaou cytology: results from the European equivocal or mildly abnormal 
Papanicolaou cytology study. Cancer Cytopathology, Vol.119, No.3, pp.158-166  
Serrano, M. (1997). The Tumor Suppressor Protein p16INK4a. Experimental Cell Research, 
Vol.237, pp.7–13Shi, J., Liu, H., Wilkerson, M., Huang, Y., Meschter, S., Dupree, W., 
Schuerch, C. & Lin, F. (2007). Evaluation of p16INK4a, minichromosome 
maintenance protein 2, DNA topoisomerase IIalpha, ProEX C, and 
p16INK4a/ProEX C in cervical squamous intraepithelial lesions. Human Pathology, 
Vol.38, pp.1335-1344 
www.intechopen.com
 
Immunohistochemistry in the Diagnosis of Squamous Intraepithelial Lesions of the Uterine Cervix 
 
63 
Snijders, P., Steenbergen, R., Heideman, D., & Meijer, C. (2006). HPV-mediated cervical 
carcinogenesis: concepts and clinical implications. Journal of Pathology, Vol.208, 
pp.152–164 
Snijders, P.J., Heideman, D.A. & Meijer, C.J. (2010). Methods for HPV detection in exfoliated 
cell and tissue specimens. APMIS, Vol.118, No.6-7, pp.520-528 
Southern, S., McDicken, I. & Herrington, C.S. (2000). Evidence for keratinocyte 
immortalization in high-grade squamous intraepithelial lesions of the cervix 
infected with high-risk human papillomaviruses. Laboratory Investigation, Vol.80, 
pp.539–544 
Stanley, M. (2010). HPV - immune response to infection and Vaccination. Infectious Agents 
and Cancer, Vol.5, pp.19 
Straight, S.W., Hinkle, P.M., Jewers, R.J. & McCance, D.J. (1993). The E5 Oncoprotein of 
Human Papillomavirus Type 16 Transforms Fibroblasts and Effects the 
Downregulation of the Epidermal Growth Factor Receptor in Keratinocytes. Journal 
of Virology, Vol.67, No.8, pp.4521–4532 
Talbert-Slagle, K. & DiMaio, D. (2009). The bovine papillomavirus E5 protein and the PDGF 
beta receptor: it takes two to tango. Virology, Vol.384, No.2, pp.345–351 
Tambouret, R.H., Misdraji, J. & Wilbur, D.C. (2008). Longitudinal clinical evaluation of a 
novel antibody cocktail for detection of high-grade squamous intraepithelial lesions 
on cervical cytology specimens. Archives of Pathology and Laboratory Medicine, 
Vol.132, No.6, pp.918-925 
Tan, G.C., Norlatiffah, S., Sharifah, N.A., Razmin, G., Shiran, M.S., Hatta, A.Z. & Paul-Ng, 
H.O. (2010). Immunohistochemical study of p16 INK4A and survivin expressions in 
cervical squamous neoplasm. Indian Journal of Pathology and Microbiology, Vol.53, 
pp.1-6 
The FUTURE I/II Study Group. (2010). Four year efficacy of prophylactic human 
papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and 
vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. 
BMJ, Vol.340, pp.c3493 
Tsoumpou, I., Arbyn, M., Kyrgiou, M., Wentzensen, N., Koliopoulos, G., Martin-Hirsch, P., 
Malamou-Mitsi, V. & Paraskevaidis, E. (2009). p16INK4a immunostaining in 
cytological and histological specimens from the uterine cervix: a systematic review 
and meta-analysis. Cancer Treatment Reviews, Vol.35, No.3, pp.210–220 
Van Niekerk, D., Guillaud, M., Matisic, J., Benedet, J., Freeberg, J., Follen, M., et al. (2007). 
p16 and MIB1 improve the sensitivity and specificity of the diagnosis of high grade 
squamous intraepithelial lesions: Methodological issues in a report of 447 biopsies 
with consensus diagnosis and HPV HCII testing. Gynecologic Oncology, Vol.107, 
pp.S233–240. 
Volgareva, G., Zavalishina, L., Andreeva, Y., Frank, G., Krutikova, E., Golovina, D. et al. 
(2004). Protein p16 as a marker of dysplastic and neoplastic alterations in cervical 
epithelial cells. BMC Cancer, Vol. 4, pp.58 
Voss, J.S., Kipp, B.R., Campion, M.B., Sokolova, I.A., Henry, M.R., Halling, K.C. & Clayton, 
A.C.. (2009). Comparison of fluorescence in situ hybridization, hybrid capture 2 
and polymerase chain reaction for the detection of high-risk human papillomavirus 
in cervical cytology specimens. Analytical and Quantitative Cytology and Histology, 
Vol.31, No.4, pp.208-216 
www.intechopen.com
Human Papillomavirus and Related Diseases  
– From Bench to Bedside – A Clinical Perspective 
 
64
Walboomers, J., Jacobs, M., Manos, M., Bosch, F.X., Kummer, J.A., Shah, K.V., Snijders, 
P.J.F., Peto, J., Meijer, C. & Munoz, N. (1999).  Human papillomavirus is a necessary 
cause of invasive cervical cancer worldwide. Journal of Pathology, Vol.189, pp.12–19 
Walts, A.E. & Bose, S. (2009). p16, Ki-67, and BD ProExC immunostaining: a practical 
approach for diagnosis of cervical intraepithelial neoplasia. Human Pathology, 
Vol.40, No.7, pp.957-964,Epub 2009 Mar 9 
Wang, S.S., Trunk, M., Schiffman, M., Herrero, R., Sherman, M., Burk, R., et al. (2004). 
Validation of p16INK4a as a marker of oncogenic human papillomavirus infection 
in cervical biopsies from a population-based cohort in Costa Rica. Cancer 
Epidemiology, Biomarkers and Prevention, Vol. 13, pp.1355–1360 
Whiteside, M., Siegel, E. & Unger, E. (2008). Human Papillomavirus and Molecular 
Considerations for Cancer Risk. Cancer, Vol.113, No.10 suppl, pp.2981–2994 
Wright, T.C. (2006). Pathology of HPV infection at the cytologic and histologic levels: basis 
for a 2-tiered morphologic classificationsystem. International Journal of Gynecology 
and Obstetrics, Vol.94, No.suppl 1, pp.22–31 
Yoshida, T., Sano, T., Kanuma, T., Owada, N., Sakurai, S., Fukuda, T. & Nakajima, T. (2008). 
Immunochemical analysis of HPV L1 capsid protein and p16 protein in liquid-
based cytology samples from uterine cervical lesions. Cancer, Vol.114, No.2, pp.83-
88 
Yu, L., Wang, L., Zhong, J. & Chen, S. (2010). Diagnostic Value of p16INK4A, Ki-67, and 
Human Papillomavirus L1 Capsid Protein Immunochemical Staining on Cell 
Blocks From Residual Liquid-Based Gynecologic Cytology Specimens. Cancer 
(Cancer Cytopathology), Vol.118, pp.47–55 
Zerfass, K., Schulze, A., Spitkovsky, D., Friedman, V., Henglein, B. & Jansendurr P. (1995). 
Sequential activation of cyclin E and cyclin A gene expression by human 
papillomavirus type 16 E7 through sequences necessary for transformation. Journal 
of General Virology, Vol.69, pp.6389–6399 
Zheng, L., Liu, A.L., Qi, T., Wang, Q., Cai, Z., Su, Y.J., Hu, Y.W., Liu, G.B. & Wei, L.H. (2010). 
Human telomerase RNA gene amplification detection increases the specificity of 
cervical intraepithelial neoplasia screening. International Journal of Gynecological 
Cancer, Vol.20, No.6, pp.912-917 
zur Hausen, H. (1977). Human papilloma viruses and their possible role in squamous cell 
carcinomas. Current Topics in Microbiology and Immunology, Vol.78, pp.1–30 
zur Hausen, H. (2008). Papillomaviruses—to Vaccination and Beyond. Biochemistry 
(Moscow), Vol.73, No.5, pp.498-503 
zur Hausen, H. (2009). Papillomaviruses in the causation of human cancers — a brief 
historical account. Virology, Vol.384, pp.260–265 
www.intechopen.com
Human Papillomavirus and Related Diseases - From Bench to
Bedside - A Clinical Perspective
Edited by Dr. Davy Vanden Broeck
ISBN 978-953-307-860-1
Hard cover, 348 pages
Publisher InTech
Published online 20, January, 2012
Published in print edition January, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Cervical cancer is the second most prevalent cancer among women worldwide, and infection with Human
Papilloma Virus (HPV) has been identified as the causal agent for this condition. The natural history of cervical
cancer is characterized by slow disease progression, rendering the condition, in essence, preventable and
even treatable when diagnosed in early stages. Pap smear and the recently introduced prophylactic vaccines
are the most prominent prevention options, but despite the availability of these primary and secondary
screening tools, the global burden of disease is unfortunately still very high. This book will focus on the clinical
aspects of HPV and related disease, highlighting the latest developments in this field.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Evanthia A. Kostopoulou and George Koukoulis (2012). Immunohistochemistry in the Diagnosis of Squamous
Intraepithelial Lesions of the Uterine Cervix, Human Papillomavirus and Related Diseases - From Bench to
Bedside - A Clinical Perspective, Dr. Davy Vanden Broeck (Ed.), ISBN: 978-953-307-860-1, InTech, Available
from: http://www.intechopen.com/books/human-papillomavirus-and-related-diseases-from-bench-to-bedside-
a-clinical-perspective/immunohistochemistry-in-the-diagnosis-of-squamous-intraepithelial-lesions-of-the-
uterine-cervix
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
